Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 +1.42%77 EBITDA Margin % is 5.91% as of Jun. 2026, which is 67% above its 10-year median of 3.54. GuruFocus rates BOM:531762 with a GF Score™ of 77/100 and a GF Value™ of ₹22.81 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 957 Drug Manufacturers companies, Unjha Formulations ranks worse than 66.14% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Unjha Formulations's EBITDA for the
three
months ended in Jun. 2026 was ₹2.0 Mil. Unjha Formulations's Revenue for the
three
months ended in Jun. 2026 was ₹33.1 Mil. Therefore, Unjha Formulations's EBITDA margin for the quarter that ended in Jun. 2026 was 5.91%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Unjha Formulations EBITDA Margin % Related Terms
Unjha Formulations EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unjha Formulations (BOM:531762) has a EBITDA Margin % of 5.91% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unjha Formulations and its competitors. This is 67% above median its historical median of 3.54. Over the past decade, Unjha Formulations' EBITDA Margin % has ranged from 3.16 to 7.03. According to the industry distribution chart, Unjha Formulations ranks #633 out of 957 companies in the Drug Manufacturers industry, placing it in the top 66.1%.
Is Unjha Formulations' EBITDA Margin % too high?
Unjha Formulations' current EBITDA Margin % of 5.91% is 67% above median its 10-year median of 3.54. Over the past 10 years, this metric has ranged from a low of 3.16 to a high of 7.03. The Drug Manufacturers industry median EBITDA Margin % is 12.62. Unjha Formulations' value of 5.91% is 53.2% below this industry median. Based on the distribution chart, Unjha Formulations ranks #633 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Unjha Formulations has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #633 out of 957 companies for EBITDA Margin %. This places Unjha Formulations in the lower half of its industry. The industry median EBITDA Margin % is 12.62. Unjha Formulations' value of 5.91% is 53.2% below this benchmark. Historically, Unjha Formulations' own EBITDA Margin % has ranged from 3.16 to 7.03 over the past decade. While the company's 10-year median is 3.54 vs. the industry median of 12.62, Unjha Formulations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.62, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current EBITDA Margin % of 5.91% is 53.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current EBITDA Margin % is 5.91%, which is 67% above median its own 10-year median of 3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹22.81, compared to a current price of ₹26.50 — trading 16.2% above its estimated fair value. The current EBITDA Margin % is 5.91%, which is 67% above median its 10-year median of 3.54 and 53.2% below the Drug Manufacturers industry median of 12.62. Unjha Formulations' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current EBITDA Margin % is 5.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹26.50 is trading 16.2% above its estimated GF Value™ of ₹22.81.
GuruFocus considers Unjha Formulations to be Modestly Overvalued.
Key valuation signals for BOM:531762:
EBITDA Margin %: 5.91% (67% above median its 10-year median of 3.54)
GF Value™: ₹22.81 vs. price of ₹26.50 (16.2% above fair value)
Industry Position: 53.2% below the Drug Manufacturers median (#633 of 957)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
77GF Score
Get the complete analysis for BOM:531762
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
